

## 1 **Stability of plasma metabolomics over 10 years among women**

2 Oana A. Zeleznik, Ph.D.<sup>1</sup>, Clemens Wittenbecher, Ph.D.<sup>2,3</sup>, Amy Deik, B.A.<sup>4</sup>, Sarah Jeanfavre,  
3 M.S.<sup>4</sup>, Julian Avila-Pacheco, Ph.D.<sup>4</sup>, Bernard Rosner, Ph.D.<sup>1</sup>, Kathryn M. Rexrode, M.D.<sup>5</sup>, Clary  
4 B. Clish, Ph.D.<sup>4</sup>, Frank B. Hu, Ph.D.<sup>2</sup>, A. Heather Eliassen, Sc.D.<sup>1,6</sup>

5 <sup>1</sup>Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical  
6 School, Boston, MA, USA

7 <sup>2</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA

8 <sup>3</sup>German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany

9 <sup>4</sup>Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA

10 <sup>5</sup>Division of Women's Health, Brigham and Women's Hospital and Harvard Medical School,  
11 Boston, MA, USA

12 <sup>6</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA,

13

14 Correspondence:

15 Oana A. Zeleznik, PhD

16 Instructor in Medicine | Harvard Medical School

17 Associate Epidemiologist | Brigham and Women's Hospital

18

19 Channing Division of Network Medicine

20 181 Longwood Avenue | Boston, MA 02115

21 [ozeleznik@bwh.harvard.edu](mailto:ozeleznik@bwh.harvard.edu)

22

23 **Abstract**

24 **Background:** In epidemiological studies, samples are often collected long before  
25 disease onset or outcome assessment. Understanding the long-term stability of biomarkers  
26 measured in these samples is crucial. We estimated within-person stability over 10 years of  
27 metabolites and metabolite features (N=5938) in the Nurses' Health Study (NHS): The primary  
28 dataset included 1880 women with 1184 repeated samples donated 10 years apart while the  
29 secondary dataset included 1456 women with 488 repeated samples donated 10 years apart.

30 **Methods:** We quantified plasma metabolomics using two liquid chromatography mass  
31 spectrometry platforms (lipids and polar metabolites) at the Broad Institute (Cambridge, MA).  
32 Intra-class correlations were used to estimate long-term stability (10 years) of metabolites and  
33 were calculated as the proportion of the total variability (within-person + between-person)  
34 attributable to between-person variability. Within-person variability was estimated among  
35 participants who donated two blood samples approximately 10 years apart while between-  
36 person variability was estimated among all participants.

37 **Results:** In the primary dataset, the median ICC was 0.43 (1<sup>st</sup> quartile [Q1]: 0.36; 3<sup>rd</sup>  
38 quartile [Q3]: 0.50) among known metabolites and 0.41 (Q1: 0.34; Q3: 0.48) among unknown  
39 metabolite features. The most stable (median ICCs: 0.54-0.57) metabolite classes were  
40 nucleosides, nucleotides and analogues, phosphatidylcholine plasmalogens, diglycerides, and  
41 cholesteryl esters. The least stable (median ICCs: 0.26-0.36) metabolite classes were  
42 lysophosphatidylethanolamines, lysophosphatidylcholines and steroid and steroid derivatives.  
43 Results in the secondary dataset were similar (Spearman correlation=0.87) to corresponding  
44 results in the primary dataset.

45 **Conclusion:** Within-person stability over 10 years is reasonable for lipid, lipid-related,  
46 and polar metabolites, and varies by metabolite class. Additional studies are required to  
47 estimate within-person stability over 10 years of other metabolites groups.

## 48 Introduction

49 In epidemiological studies, samples are often collected long before disease onset or  
50 outcome assessment. Within the Nurses' Health Studies (NHS) and NHSII, several nested  
51 case-control studies investigated prospective associations of plasma biomarkers measured in  
52 samples collected >10 years before disease onset with risk of developing cancer and other  
53 chronic diseases. For example, total circulating carotenoids measured up to 20 years before  
54 diagnosis were associated with decreased risk of developing breast cancer<sup>1</sup>. In contrast, high  
55 plasma prolactin levels measured  $\geq 10$  years before diagnosis were not associated with  
56 increased risk of breast cancer while measures <10 years before diagnosis were associated  
57 with increased risk<sup>2</sup>, emphasizing that understanding how the timing of biomarkers is related to  
58 risk is critical to elucidating disease etiology. Thus, understanding the long-term within-person  
59 stability of biomarkers measured in these samples is crucial.

60 Metabolomics, which reflect the integrated effects of the genetic background, lifestyle  
61 and environmental factors<sup>3</sup>, are of particular interest in epidemiologic studies. Metabolites  
62 measured up to 23 years before diagnosis were associated with risk of ovarian cancer in NHS  
63 and NHSII<sup>4,5</sup> reflecting long-term disease-biomarker associations. We reported previously on  
64 metabolomics short-term within-person stability in these cohorts<sup>6</sup>. However, data on the long-  
65 term within-person stability of metabolomics are lacking. Here, we assessed metabolomics  
66 within-person stability over 10 years in two separate prospective case-control studies nested  
67 within a large epidemiological study, the NHS.

68

## 69 Methods

### 70 Study Population

71 In 1976, 121,701 female registered nurses aged 30-55y enrolled in the NHS with the  
72 return of a mailed questionnaire<sup>7</sup>. Participants have been followed biennially with questionnaires  
73 collecting information on reproductive history, lifestyle factors, diet, medication use, and new  
74 disease diagnoses. In 1989-1990, 32,826 NHS participants aged 43-69y contributed blood  
75 samples, as previously described<sup>8</sup>. In 2000-2002, 18,473 of these women aged 53-80y donated  
76 a second sample using a similar protocol.

77 The primary dataset was obtained from a prospective breast cancer case-control study  
78 nested within the NHS. Incident cases of breast cancer (N=940) were identified after the second  
79 blood collection among women who had no reported cancer (other than non-melanoma skin). In  
80 total, 1880 women donated a sample during the first blood collection and 1184 women donated  
81 a second blood sample approximately 10 years later.

82 The secondary dataset is from a prospective diabetes case-control study nested within  
83 the NHS. Incident cases of diabetes (N=728) were identified after the second blood collection.  
84 In total, 1456 women donated samples during the first blood collection and 488 women donated  
85 a second blood sample approximately 10 years later.

86 The study protocol was approved by the institutional review boards of the Brigham and  
87 Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating  
88 registries as required. The return of the self-administered questionnaire and blood sample was  
89 considered to imply consent.

### 90 Blood collection methods

91 The same protocol was used for both blood collections. Briefly, participants had their  
92 blood drawn in sodium heparin tubes at a nearby clinic or by their colleagues, and the blood

93 samples were shipped with an ice pack via overnight courier to our laboratory. Whole blood  
94 samples were centrifuged (2500 RPM for 20 minutes at 4°C) and aliquoted into 5 mL plasma,  
95 red blood cells and white blood cells cryotubes. Plasma samples are stored in the vapor phase  
96 of liquid nitrogen (LN2) freezers (temperature  $\leq -130^{\circ}\text{C}$ ; alarmed and monitored 24 hours a day)  
97 with LN2-rated gasketed screw tops since collection. At the time of blood collection, participants  
98 also completed a questionnaire regarding time since last meal and time of day when they  
99 completed blood collection

## 100 **Laboratory assays**

101           Metabolic profiles were assayed through a metabolomic profiling platform at the Broad  
102 Institute using a liquid chromatography tandem mass spectrometry (LC-MS) method designed  
103 to measure polar metabolites such as amino acids and lipids<sup>9-11</sup>. The relative abundance of  
104 each metabolite was determined by the integration of LC-MS peak areas, which are unitless  
105 numbers that are directly proportional to metabolite concentrations. For each measurement  
106 method (polar metabolites and lipids), pooled plasma reference samples were included every 20  
107 samples and results were standardized using the ratio of the value of the sample to the value of  
108 the nearest pooled reference multiplied by the median of all reference values for the metabolite.  
109 In each dataset, samples were assayed in pairs, with matched case-control pairs (as sets)  
110 distributed randomly within the batch, and the order of the case and controls within each pair  
111 randomly assigned. Therefore, the case and its control were always directly adjacent to each  
112 other in the analytic run, thereby limiting variability in platform performance across matched  
113 case-control pairs. In addition, YY quality control (QC) samples, to which the laboratory was  
114 blinded, were also profiled. These were randomly distributed among the participants' samples.

115           Hydrophilic interaction liquid chromatography (HILIC) analyses of water soluble  
116 metabolites in the positive ionization mode were conducted using an LC-MS system comprised  
117 of a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp.; Marlborough, MA) coupled to a Q

118 Exactive mass spectrometer (Thermo Fisher Scientific; Waltham, MA). Metabolites were  
119 extracted from plasma (10  $\mu$ L) using 90  $\mu$ L of acetonitrile/methanol/formic acid (74.9:24.9:0.2  
120 v/v/v) containing stable isotope-labeled internal standards (valine-d8, Sigma-Aldrich; St. Louis,  
121 MO; and phenylalanine-d8, Cambridge Isotope Laboratories; Andover, MA). The samples were  
122 centrifuged (10 min, 9,000 x g, 4°C), and the supernatants were injected directly onto a 150 x 2  
123 mm, 3  $\mu$ m Atlantis HILIC column (Waters; Milford, MA). The column was eluted isocratically at a  
124 flow rate of 250  $\mu$ L/min with 5% mobile phase A (10 mM ammonium formate and 0.1% formic  
125 acid in water) for 0.5 minute followed by a linear gradient to 40% mobile phase B (acetonitrile  
126 with 0.1% formic acid) over 10 minutes. MS analyses were carried out using electrospray  
127 ionization in the positive ion mode using full scan analysis over 70-800 m/z at 70,000 resolution  
128 and 3 Hz data acquisition rate. Other MS settings were: sheath gas 40, sweep gas 2, spray  
129 voltage 3.5 kV, capillary temperature 350°C, S-lens RF 40, heater temperature 300°C,  
130 microscans 1, automatic gain control target 1e6, and maximum ion time 250 ms. Metabolites  
131 measured with this method will be referred to as HILIC-positive metabolites.

132 Plasma lipids were profiled using a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp.;  
133 Marlborough, MA). Lipids were extracted from plasma (10  $\mu$ L) using 190  $\mu$ L of isopropanol  
134 containing 1,2-didodecanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids; Alabaster, AL).  
135 After centrifugation, supernatants were injected directly onto a 100 x 2.1 mm, 1.7  $\mu$ m ACQUITY  
136 BEH C8 column (Waters; Milford, MA). The column was eluted isocratically with 80% mobile  
137 phase A (95:5:0.1 vol/vol/vol 10mM ammonium acetate/methanol/formic acid) for 1 minute  
138 followed by a linear gradient to 80% mobile-phase B (99.9:0.1 vol/vol methanol/formic acid) over  
139 2 minutes, a linear gradient to 100% mobile phase B over 7 minutes, then 3 minutes at 100%  
140 mobile-phase B. MS analyses were carried out using electrospray ionization in the positive ion  
141 mode using full scan analysis over 200–1100 m/z at 70,000 resolution and 3 Hz data acquisition  
142 rate. Other MS settings were: sheath gas 50, in source CID 5 eV, sweep gas 5, spray voltage 3

143 kV, capillary temperature 300°C, S-lens RF 60, heater temperature 300°C, microscans 1,  
144 automatic gain control target 1e6, and maximum ion time 100 ms. Lipid identities were denoted  
145 by total acyl carbon number and total double bond number. Metabolites measured with this  
146 method will be referred to as C8-positive metabolites.

147 Raw data from orbitrap mass spectrometers were processed using TraceFinder 3.3  
148 software (Thermo Fisher Scientific; Waltham, MA) and Progenesis QI (Nonlinear Dynamics;  
149 Newcastle upon Tyne, UK). For each method, metabolite identities were confirmed using  
150 authentic reference standards or reference samples.

151 After exclusion of metabolites not stable with a delay in processing which is  
152 characteristic of the two blood collections<sup>6</sup> (N=35) and those missing in >10% of the participants  
153 who donated two samples (20 known compounds and 1069 unknown metabolite features), the  
154 primary dataset included 5938 metabolites (295 known compounds and 5643 unknown  
155 metabolite features) measured at both blood collections. 2519 lipids and lipid-related  
156 metabolites (153 known compounds and 2366 unknown metabolite features) were measured  
157 with the C8 column in positive mode while 3419 polar metabolites (142 known compounds and  
158 3277 unknown metabolite features) were measured with the HILIC column in positive mode.  
159 Most of the known metabolites (N=253; 86%) and 47% (N=2655) of the unknown metabolite  
160 features had coefficients of variation (CV) <25%. All metabolites were included in this study.

161 Similarly, after exclusion of metabolites not stable with a delay in processing which is  
162 characteristic of the two blood collections<sup>6</sup> (N=34) and those missing in >10% of the participants  
163 who donated two samples (16 known compounds and 427 unknown metabolite features), the  
164 secondary dataset included 3209 polar metabolites (202 known compounds and 3007 unknown  
165 metabolite features) measured at both blood collections. The secondary dataset did not include  
166 lipids and lipid-related metabolites. Most of the known metabolites (N=171; 85%) and 44%

167 (N=1326) of the unknown metabolite features had CV<25%. All metabolites were included in  
168 this study.

## 169 **Statistical Analysis**

170 Metabolite values were transformed to probit scores within in each blood collection and  
171 dataset. We estimated within-person stability over 10 years by calculating intra-class correlation  
172 (ICC) using liner mixed models with participant IDs as a random effect. We followed the  
173 approach developed by Dr. Rosner et. al<sup>12</sup> to estimate ICCs on the probit scale and transform  
174 these back to the ranked scale. Within-person variability was estimated among participants who  
175 donated two blood samples approximately 10 years apart (N=1184) while between-person  
176 variability was estimated among all participants (N=1880). ICCs were calculated as the  
177 proportion of the total variability (within-person + between-person) attributable to between-  
178 person variability. We also calculated median % change in metabolite levels over 10 years. In  
179 sensitivity analyses, we restricted to fasting women (N=1309 of which 765 donated 2 samples),  
180 women with stable BMI ( $\leq 2\text{kg/m}^2$  change in BMI between the two blood collections, N=706),  
181 women with change in BMI ( $> 2\text{kg/m}^2$  change in BMI between the two blood collections, N=478),  
182 postmenopausal women not using postmenopausal hormone therapy at either timepoint (N=577  
183 of which 223 donated 2 samples), and to women without breast cancer at both blood collections  
184 (N=940 of which 592 donated 2 samples). The secondary dataset included only women who  
185 were fasting for >8 hours. To assess differences in ICCs between the two datasets, we  
186 calculated % absolute change in ICCs between the primary and secondary dataset.

## 187 **Results**

### 188 **Study population characteristics**

189 Women in the primary dataset had a mean age of 56 years at the first blood collection  
190 (N=1880) and 66 years at the second blood collection (N=1184). Participant characteristics  
191 were similar at the two blood collections (Table 1) with some exceptions: more women reported

192 being postmenopausal, past smokers and fasting >8 hours at the second blood collection  
193 compared to the first blood collection. Women in the secondary dataset (first collection N=1456,  
194 second collection N=488) were similar to the fasting women (first collection N=1309, second  
195 collection N=1062) in the primary dataset (Supplementary Table 1).

196 **Table 1: Characteristics of study participants by blood collection in the primary dataset.**

	First collection	Second collection
<b>N</b>	1880	1184
<b>Age, y</b>	55.57 (6.92)	66.46 (6.87)
<b>BMI, kg/m<sup>2</sup></b>	25.37 (4.53)	26.57 (5.11)
<b>Physical activity, MET-hrs/wk</b>	16.34 (20.00)	19.58 (20.78)
<b>Alcohol consumption, g/day</b>	6.71 (10.95)	5.81 (9.45)
<b>AHEI<sup>^</sup></b>	47.31 (10.67)	50.16 (9.98)
<b>Menopausal status, %</b>		
<b>Premenopausal</b>	479 (25.5)	8 (0.7)
<b>Postmenopausal, no PMH<sup>#</sup> use</b>	577 (30.7)	374 (31.6)
<b>Postmenopausal, PMH<sup>#</sup> use</b>	587 (31.2)	788 (66.6)
<b>Missing/Dubious</b>	237 (12.6)	14 (1.2)
<b>Fasting (&gt;8h), %</b>	1309 (69.6)	1062 (89.7)
<b>Smoking, %</b>		
<b>Never</b>	888 (47.4)	551 (46.7)
<b>Past</b>	748 (39.9)	575 (48.7)
<b>Current</b>	238 (12.7)	55 (4.7)
<b>Race, %</b>		
<b>White</b>	1853 (98.6)	1173 (99.1)
<b>Black</b>	14 (0.7)	4 (0.3)
<b>Asian</b>	10 (0.5)	5 (0.4)
<b>Other/missing</b>	3 (0.2)	2 (0.2)

<sup>^</sup>Alternative Healthy Eating Index, calculated without alcohol consumption

<sup>#</sup>Postmenopausal Hormone

197


### 198 **Metabolomics stability over 10 years in the primary dataset**

199 For known metabolites, the median ICC was 0.43 (1<sup>st</sup> quartile [Q1]: 0.36; 3<sup>rd</sup> quartile  
200 [Q3]: 0.50). For unknown metabolite features, the median ICC was 0.41 (Q1: 0.34; Q3: 0.48).

201 Among lipids and lipid-related metabolites, the median ICC for known metabolites was 0.44 (Q1:

202 0.38; Q3: 0.51) while for the unknown metabolite features it was 0.41 (Q1: 0.35; Q3: 0.47;  
203 Figure 1). Among polar metabolites, the median ICC for known metabolites was 0.42 (Q1: 0.33;  
204 Q3: 0.49) while for the unknown metabolite features it was 0.41 (Q1: 0.34; Q3: 0.48; Figure 1).  
205 The median ICC was 0.43 (Q1: 0.36; Q3: 0.50) among metabolites with  $CV < 25\%$  and 0.39 (Q1:  
206 0.33; Q3: 0.46) among metabolites with  $CV \geq 25\%$ . The median % difference in known metabolite  
207 levels between the two collections, calculated from the raw values, was -5.25% (Q1: -14.80%,  
208 Q3: 0.92%; Supplementary Table 2). The median % difference in unknown metabolite feature  
209 levels between the two collections, calculated from the raw values, was 0.03% (Q1: -6.80%,  
210 Q3: 4.13%; Supplementary Table 2).

211 **Figure 1: Metabolomics stability over 10 years by measurement method (lipid and lipid-related vs.**  
212 **polar metabolites) and known metabolites (N=295) vs. unknown metabolite features (N=5643).**




213

214

215 Among known metabolites, ICCs varied by metabolite class (Figure 2). The most stable  
216 metabolite classes were nucleosides, nucleotides, and analogues (median ICC: 0.57; Q1: 0.54;  
217 Q3: 0.60), phosphatidylcholine (PC) plasmalogens (median ICC: 0.54; Q1: 0.50; Q3: 0.56),

218 diglycerides (DG; median ICC: 0.53; Q1: 0.51; Q3: 0.54), and cholesteryl esters (CE; median  
219 ICC: 0.53; Q1: 0.51; Q3: 0.56). The least stable metabolite classes were steroids and steroid  
220 derivatives (median ICC: 0.26; Q1: 0.25; Q3: 0.28), lysophosphatidylcholines (LPC; median  
221 ICC: 0.36; Q1: 0.27; Q3: 0.40) and lysophosphatidylethanolamines (LPE; median ICC: 0.36; Q1:  
222 0.33; Q3: 0.38).

223 **Figure 2: Metabolomics stability over 10 years by metabolite class.** Results from known metabolites are  
224 included in this figure. Metabolomics classes with less than three metabolites were added to the class  
225 Other.




226  
227  
228 We observed similar ICCs across participant strata in sensitivity analyses (Figure 3,  
229 Supplementary Table 2, and Supplementary Figure 1). ICCs of known metabolites estimated  
230 among all women (median ICC: 0.43, Q1: 0.36; Q3: 0.50) were similar to those estimated  
231 among fasting women (median ICC: 0.45, Q1: 0.37; Q3: 0.52), women with stable BMI (median  
232 ICC: 0.43, Q1: 0.36; Q3: 0.51) and women with a change in BMI (median ICC: 0.41, Q1: 0.33;  
233 Q3: 0.48). A similar pattern was observed for unknown metabolite features (all women: median

234 ICC: 0.41 (Q1:0.34; Q3:0.48); fasting women: median ICC: 0.42 (Q1: 0.35; Q3: 0.49); women  
235 with stable BMI: median ICC: 0.42 (Q1: 0.35; Q3: 0.48); women with unstable BMI: median ICC:  
236 0.40 (Q1: 0.33; Q3: 0.47)). Among postmenopausal women not using postmenopausal hormone  
237 therapy at either collection, the median ICC was 0.44 (Q1: 0.36; Q3: 0.53) for known  
238 metabolites and 0.41 (Q1: 0.33; Q3: 0.49) for unknown metabolite features (data not shown).  
239 Among control samples only, the median ICC was 0.44 (Q1: 0.37; Q3: 0.51) for known  
240 metabolites and 0.41 (Q1: 0.35; Q3: 0.49) for unknown metabolite features (data not shown).  
241 Notably, metabolites stable among all women were also stable when assessed in different  
242 participant strata (for example, N6,N6-dimethyllysine ICC ranges between 0.82 and 0.84 across  
243 participant strata; Table 2). Similarly, metabolites with low ICC among all women were also not  
244 stable when assessed in the different participant strata (for example, palmitoylethanolamide ICC  
245 ranges between 0.03 and 0.06 across subgroups; Table 2).

246 **Figure 3: Metabolomics stability over 10 years by known metabolites (N=295) vs. unknown metabolite**  
247 **features (N=5643).** ICCs were estimated among all participants (N=1880 of which 1184 donated 2  
248 samples), fasting participants (N=1309 of which 765 donated 2 samples), and among participants with  
249 stable (N=706) or unstable BMI (N=478 samples). The stable BMI group includes participants with  
250  $\leq 2\text{kg/m}^2$  change in BMI between the two blood collections. The unstable BMI group includes participants  
251 with  $>2\text{kg/m}^2$  change in BMI between the two blood collections.

252



253

254 **Table 2: Most and least stable metabolites.** ICCs were estimated among four participant subgroups: all  
 255 participants (N=1184 repeated samples and N=696 unique samples), fasting participants (N=765  
 256 repeated and N=544 unique samples), and among participants with stable (N=706 repeated samples) or  
 257 unstable BMI (N=478 repeated samples). The stable BMI group includes participants with  $\leq 2\text{kg/m}^2$   
 258 difference in BMI between the two blood collections. The unstable BMI group includes participants with  
 259  $>2\text{kg/m}^2$  difference in BMI between the two blood collections.

	Metabolite name	Metabolite class	Intra-class correlation			
			All	Fasting	Stable BMI	Unstable BMI
Most stable metabolites	N6,N6-dimethyllysine	Organic acids and derivatives	0.82	0.84	0.83	0.83
	DMGV	Other	0.72	0.73	0.73	0.71
	N-acetyloronithine	Organic acids and derivatives	0.69	0.72	0.7	0.68
	C34:2 PC plasmalogen	Phosphatidylcholine plasmalogens	0.66	0.67	0.66	0.61
	C38:4 PC	Phosphatidylcholines	0.65	0.66	0.66	0.63
	glycine	Amino acids	0.65	0.64	0.65	0.62
	C5-DC carnitine	Carnitines	0.64	0.63	0.66	0.62
	N4-acetylcytidine	Nucleosides, nucleotides, and analogues	0.64	0.62	0.68	0.62
	ADMA/SDMA	Organic acids and derivatives	0.62	0.63	0.66	0.65
	C36:1 PE plasmalogen	Phosphatidylethanolamine plasmalogens	0.62	0.62	0.64	0.59
Least stable metabolites	1-methylhistidine	Other	0.21	0.18	0.21	0.25
	4-hydroxyhippurate	Other	0.21	0.19	0.18	0.26
	acetaminophen	Other	0.2	0.18	0.21	0.21
	guanosine	Other	0.2	0.20	0.17	0.23
	allantoin	Other	0.18	0.21	0.15	0.20
	hydroxyproline	Carboxylic acids and derivatives	0.18	0.12	0.17	0.17
	methyl N-methylanthranilate	Other	0.17	0.13	0.14	0.22
	trimethylamine-N-oxide	Other	0.16	0.15	0.12	0.24
	ectoine	Other	0.09	0.08	0.08	0.10
	palmitoylethanolamide	Other	0.05	0.03	0.05	0.06

260


261

### 262 **Metabolomics stability over 10 years in the secondary dataset**

263 Results in the secondary dataset, which included known polar metabolites and fasting  
 264 women, were similar to results for known polar metabolites among fasting women in the primary  
 265 dataset (Pearson correlation=0.89, Spearman correlation=0.87; Figure 4, Supplementary Table  
 266 3). In the secondary dataset, the median ICC among known metabolites was 0.43 (Q1: 0.34;

267 Q3: 0.51), similar to the median ICC of 0.43 (Q1: 0.35; Q3: 0.52) among unknown metabolite  
268 features. Among known metabolites for which we were able to estimate ICCs in both datasets  
269 (N=105), 52 (50%) metabolites had % ICC absolute difference <10% and 82 (78%) had %  
270 absolute difference <20%. The metabolites with the lowest % absolute ICC difference between  
271 the two datasets were 1,7-dimethyluric acid (primary dataset ICC: 0.42; secondary dataset ICC:  
272 0.42), caffeine (primary dataset ICC: 0.42; secondary dataset ICC: 0.43), and creatinine  
273 (primary dataset ICC: 0.60; secondary dataset ICC: 0.60). Similarly, 17 metabolites ranked  
274 among the top 25 most stable metabolites in the primary dataset were also ranked among the  
275 25 most stable metabolites in the secondary dataset.

276 **Figure 4: Metabolomics stability over 10 years in the primary and secondary datasets.** The primary  
277 dataset was restricted to polar metabolites and fasting women to match the secondary dataset. Intra-  
278 class correlations (ICCs) in the two datasets are shown as boxplots (panel A) and by metabolite class in a  
279 scatter plot (panel B). The correlation was estimated using Spearman's rank correlation coefficient.



280

281

## 282 Discussion

283 We estimated within-person stability over ten years for 5938 metabolites (295 known  
284 compounds and 5643 unknown metabolite features) among 1880 women. Most metabolites  
285 were reasonably stable over ten years with a median ICC of 0.43 for known metabolites and  
286 0.41 from unknown metabolite features. Within-person stability over ten years varied by

287 metabolite class. In secondary analyses, we performed a partial replication of polar metabolites  
288 in another data set of 1456 fasting women; findings were similar.

289 To the best of our knowledge, this is the first study to assess within-person stability of  
290 metabolomic profiles over 10 years. We have assessed within-person stability of metabolites  
291 over shorter periods of times, 1-2 years<sup>6</sup>. Notably, although the within-person stability was  
292 attenuated, the metabolite classes that were the most stable over 1-2 years were also the most  
293 stable over 10 years. For example, cholesteryl esters, phosphatidylcholine plasmalogens and  
294 diglycerides had the high median ICCs over 1-2 years (median ICC: 0.76, 0.76, 0.73) and over  
295 10 years (median ICC: 0.53, 0.55, 0.53). Nucleosides, nucleotides, and analogues were the  
296 most stable class over 10y (10y ICC=0.57, 1-2y ICC = 0.55). Steroid and steroid derivatives was  
297 the least stable class over 1-2 years (median ICC = 0.36) and over 10 years (median ICC =  
298 0.26).

299 Our results show that although the within-person stability decreases over time,  
300 metabolites are reasonably stable over 10 years. The reduced within-person stability over 10  
301 years compared to 1-2 years is due to multiple sources of variation. True changes in metabolite  
302 levels over long periods of time are the most important one. Changes over 10 years in personal,  
303 behavioral, and lifestyle factors such as age, BMI, menopausal status, exposure to  
304 postmenopausal hormone therapy, diet, physical activity are likely to affect metabolite levels.  
305 For example, acetaminophen, a drug often used sporadically for different types of aches and  
306 pains, had a low with-in-person stability, likely reflecting different windows of exposure.  
307 Furthermore, some diet related metabolites (e.g. trimethylamine-N-oxide (TMO)<sup>13</sup>, pipercolic  
308 acid<sup>14</sup>) tended to show low within-person stability over 10 years. Notably, within person stability  
309 over time among triglycerides (TAG) varied by saturation level and length of the fatty acyl  
310 chains. Most highly unsaturated TAGs with long fatty acyl chains, which are associated with  
311 long-term vegetable intake<sup>14</sup>, tended to be more stable over time compared to less unsaturated

312 TAGs with shorter fatty acyl chains. While changes in behaviors and exposures result in a  
313 reduced 10 years within-person stability of metabolites, it is important to note that we expect  
314 changes in metabolite levels in response to changes in these factors. Furthermore, we study  
315 metabolites to identify new risk and disease biomarkers because they reflect changes in these  
316 factors and are considered a representation of the metabolic state of an individual, the  
317 integrated effects of their genetic background, lifestyle, and environmental exposures<sup>3</sup>. A critical  
318 feature of some of the most widely applied clinical disease risk markers, such as standard blood  
319 lipids, is their responsiveness to pharmacological and lifestyle-based risk prevention.

320 Long-term storage may represent another source of variation. However, the samples in  
321 these cohorts are stored at ultra-low temperatures ( $\leq -196^{\circ}\text{C}$ ) which were shown to limit the  
322 negative effects of long-term storage<sup>15</sup>. Additionally, we have identified metabolites measured in  
323 these long-term stored samples that were significantly associated with cancer and other chronic  
324 diseases in multiple studies (e.g., pancreatic<sup>16</sup>, ovarian<sup>4,5</sup>, breast<sup>17,18</sup> and prostate cancer<sup>19</sup>,  
325 rheumatoid arthritis<sup>20</sup> and cardiovascular disease<sup>21</sup>), suggesting that storage time does not  
326 substantially impact biomarker-disease associations. Furthermore, for a considerable subset of  
327 metabolites (e.g., cotinine, trigonelline, caffeine, pantothenate, C45:3 TAG, C54:9 TAG), we  
328 also observed relatively large median % differences over 10 years (-47%/+58%) and, at the  
329 same time, reasonably high ICCs ( $>0.4$ ), suggesting that potential changes in metabolite levels  
330 due to long term-storage are similar across individuals.

331 For a subset of metabolites, two additional sources of variation have to be considered.  
332 To leverage the large coverage of the assay, we did not exclude metabolites with low technical  
333 reproducibility from the analysis. Furthermore, the samples in this analysis are subject to  
334 delayed processing (24-48 hours after sample collection). We excluded metabolites where we  
335 have documented variation with a delay in processing<sup>6</sup>, but this information was not available for

336 all known metabolites, and not available for any of the unknown metabolite features. Notably,  
337 both factors would result in a potential underestimation of long-term within-person stability.

338 The 10-year within-person stability of metabolites is similar to other plasma biomarkers  
339 measured in the NHS. For example, postmenopausal hormone levels (estradiol ICC = 0.69,  
340 testosterone ICC = 0.71, sex hormone-binding globulin ICC = 0.74, and  
341 dehydroepiandrosterone sulfate ICC = 0.54)<sup>22</sup>, 25-hydroxyvitamin D (ICC = 0.51)<sup>23</sup> and prolactin  
342 (ICC=0.39)<sup>2</sup> all showed high or moderate within-person reproducibility over 10 years, whereas  
343 dietary biomarkers such as carotenoids (ICCs ranged between 0.3 for  $\beta$ -carotene to 0.54 for  
344 lutein and zeaxanthin)<sup>1</sup> and fluorescent oxidation products (ICCs range from 0.14 to 0.30)<sup>24</sup>  
345 showed moderate or modest long-term within-person stability. While long-term stability should  
346 be factored into result interpretation, many of the most predictive and widely used biomarkers  
347 have similar within-person stability over 10 years in this cohort. For example, plasma cholesterol  
348 has a 10 years ICC of 0.39 and is highly predictive of coronary artery disease risk in our<sup>25-27</sup> and  
349 other cohorts.

350 Our study has several strengths and limitations. We were able to assess within-person  
351 stability over 10 years for over 295 known metabolites (polar metabolites, and lipids and lipid-  
352 related metabolites) and 5643 unknown metabolite features. However, our study did not include  
353 other metabolite groups such as fatty acids, carbohydrates, alcohols, and vitamins. We had a  
354 large sample size and were able to conduct a partial replication for a subset of the measured  
355 metabolites among fasting women, but our study included mostly Caucasian women limiting its  
356 generalizability. It should also be noted that the samples used in this analysis were subject to  
357 delayed processing (blood collection characteristic in the NHS). While we excluded metabolites  
358 known to vary with a delay in processing, this information was not available for all analyzed  
359 metabolites. Additionally, we did not exclude metabolites with low technical reproducibility. Due  
360 to these factors, the ICCs presented here may include variation due to technical reproducibility

361 and/or differential delay in processing between the two blood collections which can potentially  
362 result in an underestimation of within-person stability over time.

363 In summary, our study showed that metabolites are reasonably stable over 10 years, a  
364 time interval characteristic of prospective epidemiologic studies of chronic disease. In a  
365 secondary dataset, we were able to replicate our findings for a subset of metabolites among  
366 fasting women. Stability over ten years varied by metabolite class. While the 10 years stability of  
367 metabolites should be an important factor when interpreting results, it is equally important to  
368 consider the sources of variation that influence long-term within-person stability of metabolites.  
369 Findings from this study represent a comprehensive resource for the design of future studies  
370 into disease risk associations of specific metabolites and/or metabolite classes.

371

372 **Acknowledgements.** This study was funded by the National Institutes of Health (UM1  
373 CA186107, P01 CA087969, R01 CA49449, R01 DK112940). The content is solely the  
374 responsibility of the authors and does not necessarily represent the official views of the National  
375 Institutes of Health. We would like to thank the participants and staff of the Nurses' Health  
376 Studies for their valuable contributions as well as the following state cancer registries for their  
377 help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH,  
378 NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full  
379 responsibility for analyses and interpretation of these data.

380

## 381 References

382

- 383 1. Eliassen, A.H., *et al.* Plasma carotenoids and risk of breast cancer over 20 y of follow-up. *Am J*  
384 *Clin Nutr* **101**, 1197-1205 (2015).
- 385 2. Tworoger, S.S., *et al.* A 20-year prospective study of plasma prolactin as a risk marker of breast  
386 cancer development. *Cancer Res.* **73**, 4810-4819 (2013).
- 387 3. Krumsiek, J., Bartel, J. & Theis, F.J. Computational approaches for systems metabolomics.  
388 *Current opinion in biotechnology* **39**, 198-206 (2016).
- 389 4. Zeleznik, O.A., *et al.* Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and  
390 Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study. *J Natl Cancer Inst* (2019).
- 391 5. Zeleznik, O.A., *et al.* A prospective analysis of circulating plasma metabolites associated with  
392 ovarian cancer risk. *Cancer Res.* (2020).
- 393 6. Townsend, M.K., *et al.* Reproducibility of metabolomic profiles among men and women in 2  
394 large cohort studies. *Clinical chemistry* **59**, 1657-1667 (2013).
- 395 7. Hankinson, S.E., *et al.* Plasma prolactin levels and subsequent risk of breast cancer in  
396 postmenopausal women. *J. Natl. Cancer Inst.* **91**, 629-634 (1999).
- 397 8. Tworoger, S.S., Sluss, P. & Hankinson, S.E. Association between plasma prolactin concentrations  
398 and risk of breast cancer among predominately premenopausal women. *Cancer research* **66**,  
399 2476-2482 (2006).
- 400 9. Mascanfroni, I.D., *et al.* Metabolic control of type 1 regulatory T cell differentiation by AHR and  
401 HIF1- $\alpha$ . *Nature medicine* **21**, 638 (2015).
- 402 10. O'sullivan, J.F., *et al.* Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes.  
403 *The Journal of clinical investigation* **127**, 4394-4402 (2017).
- 404 11. Paynter, N.P., *et al.* Metabolic predictors of incident coronary heart disease in women.  
405 *Circulation* **137**, 841-853 (2018).
- 406 12. Rosner, B. & Glynn, R.J.J.S.i.m. Interval estimation for rank correlation coefficients based on the  
407 probit transformation with extension to measurement error correction of correlated ranked  
408 data. **26**, 633-646 (2007).
- 409 13. Bennett, B.J., *et al.* Trimethylamine-N-oxide, a metabolite associated with atherosclerosis,  
410 exhibits complex genetic and dietary regulation. **17**, 49-60 (2013).
- 411 14. Wang, F., *et al.* Mapping the Metabolic Profiles of Long-Term Vegetable, Fruit, and Fruit Juice  
412 Consumption. **4**, 787-787 (2020).
- 413 15. Tworoger, S.S. & Hankinson, S.E. Use of biomarkers in epidemiologic studies: minimizing the  
414 influence of measurement error in the study design and analysis. *Cancer Causes & Control* **17**,  
415 889-899 (2006).
- 416 16. Mayers, J.R., *et al.* Elevation of circulating branched-chain amino acids is an early event in  
417 human pancreatic adenocarcinoma development. *Nature medicine* **20**, 1193-1198 (2014).
- 418 17. Zeleznik, O.A., *et al.* Branched chain amino acids and risk of breast cancer. *medRxiv*,  
419 2020.2008.2031.20185470 (2020).
- 420 18. Zeleznik, O.A., *et al.* Circulating amino acids and amino acid-related metabolites and risk of  
421 breast cancer among predominantly premenopausal women. *NPJ breast cancer* **7**, 1-10 (2021).
- 422 19. Dickerman, B.A., *et al.* A metabolomics analysis of adiposity and advanced prostate cancer risk in  
423 the Health Professionals Follow-up Study. *Metabolites* **10**, 99 (2020).
- 424 20. Chu, S.H., *et al.* Circulating plasma metabolites and risk of rheumatoid arthritis in the Nurses'  
425 Health Study. *Rheumatology* **59**, 3369-3379 (2020).
- 426 21. Li, J., *et al.* The Mediterranean diet, plasma metabolome, and cardiovascular disease risk.  
427 *European heart journal* **41**, 2645-2656 (2020).

- 428 22. Zhang, X., Tworoger, S.S., Eliassen, A.H. & Hankinson, S.E. Postmenopausal plasma sex hormone  
429 levels and breast cancer risk over 20 years of follow-up. *Breast cancer research and treatment*  
430 **137**, 883-892 (2013).
- 431 23. Eliassen, A.H., *et al.* Plasma 25-hydroxyvitamin D and risk of breast cancer in women followed  
432 over 20 years. *Cancer Res.* **76**, 5423-5430 (2016).
- 433 24. Fortner, R.T., Tworoger, S.S., Wu, T. & Eliassen, A.H. Plasma fluorescent oxidation products and  
434 breast cancer risk: repeated measures in the Nurses' Health Study. *Breast cancer research and*  
435 *treatment* **141**, 307-316 (2013).
- 436 25. Cahill, L.E., Sacks, F.M., Rimm, E.B. & Jensen, M.K. Cholesterol efflux capacity, HDL cholesterol,  
437 and risk of coronary heart disease: a nested case-control study in men. *J. Lipid Res.* **60**, 1457-  
438 1464 (2019).
- 439 26. Jensen, M.K., Rimm, E.B., Furtado, J.D. & Sacks, F.M. Apolipoprotein C-III as a potential  
440 modulator of the association between HDL-cholesterol and incident coronary heart disease.  
441 *Journal of the American Heart Association* **1**, e000232 (2012).
- 442 27. Mendivil, C.O., Rimm, E.B., Furtado, J., Chiuve, S.E. & Sacks, F.M. Low-density lipoproteins  
443 containing apolipoprotein C-III and the risk of coronary heart disease. *Circulation* **124**, 2065-  
444 2072 (2011).

445